KLK3 and prostate cancer: In the European Randomized study of Screening for Prostate Cancer trial of prostate cancer screening, the cumulative incidence of advanced-stage cancer (metastatic disease or measured PSA more than 100 ng/mL) was reduced by 48% in the screened group.